JPH07505646A - 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト - Google Patents
神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニストInfo
- Publication number
- JPH07505646A JPH07505646A JP5518094A JP51809493A JPH07505646A JP H07505646 A JPH07505646 A JP H07505646A JP 5518094 A JP5518094 A JP 5518094A JP 51809493 A JP51809493 A JP 51809493A JP H07505646 A JPH07505646 A JP H07505646A
- Authority
- JP
- Japan
- Prior art keywords
- biphenyl
- pharmaceutically acceptable
- methyl
- tetrazol
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000007830 nerve conduction Effects 0.000 title claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 11
- 230000001771 impaired effect Effects 0.000 title claims description 6
- 208000032131 Diabetic Neuropathies Diseases 0.000 title claims description 5
- 229940123413 Angiotensin II antagonist Drugs 0.000 title claims 6
- 239000002333 angiotensin II receptor antagonist Substances 0.000 title claims 6
- 239000005557 antagonist Substances 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 15
- 230000006735 deficit Effects 0.000 claims description 14
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- -1 2'-(IH-tetrazol-5-yl)bi phenyl-4-yl Chemical group 0.000 claims description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 2
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 claims description 2
- 229940126601 medicinal product Drugs 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 2
- FSJCYXPMWQPVOS-UHFFFAOYSA-N 2-ethyl-4-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methoxy]quinoline Chemical compound C=12C=CC=CC2=NC(CC)=CC=1OCC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 FSJCYXPMWQPVOS-UHFFFAOYSA-N 0.000 claims 3
- YILJWHUIUCRKEU-UHFFFAOYSA-N 2-butyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazo[4,5-b]pyridine Chemical compound CCCCC1=NC2=CC=CN=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=NN1 YILJWHUIUCRKEU-UHFFFAOYSA-N 0.000 claims 2
- PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 claims 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims 1
- 241000577218 Phenes Species 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 230000037396 body weight Effects 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- KOFLVDBWRHFSAB-UHFFFAOYSA-N 1,2,4,5-tetrahydro-1-(phenylmethyl)-5,9b(1',2')-benzeno-9bh-benz(g)indol-3(3ah)-one Chemical compound C1C(C=2C3=CC=CC=2)C2=CC=CC=C2C23C1C(=O)CN2CC1=CC=CC=C1 KOFLVDBWRHFSAB-UHFFFAOYSA-N 0.000 description 1
- ZQKMVHXJWJNEQG-UHFFFAOYSA-N 1h-1,6-naphthyridin-2-one Chemical compound C1=NC=CC2=NC(O)=CC=C21 ZQKMVHXJWJNEQG-UHFFFAOYSA-N 0.000 description 1
- 229940118148 Aldose reductase inhibitor Drugs 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 101150093335 KIN1 gene Proteins 0.000 description 1
- 241001139947 Mida Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002082 fibula Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- PSXRWZBTVAZNSF-UHFFFAOYSA-N hydron;quinoline;chloride Chemical compound Cl.N1=CC=CC2=CC=CC=C21 PSXRWZBTVAZNSF-UHFFFAOYSA-N 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929208116A GB9208116D0 (en) | 1992-04-13 | 1992-04-13 | Therapeutic agents |
| GB9208116.5 | 1992-04-13 | ||
| GB929211289A GB9211289D0 (en) | 1992-05-28 | 1992-05-28 | Heterocyclic therapeutic agents |
| GB9211289.5 | 1992-05-28 | ||
| PCT/GB1993/000732 WO1993020816A1 (en) | 1992-04-13 | 1993-04-07 | Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07505646A true JPH07505646A (ja) | 1995-06-22 |
Family
ID=26300705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5518094A Pending JPH07505646A (ja) | 1992-04-13 | 1993-04-07 | 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP0636027B1 (enExample) |
| JP (1) | JPH07505646A (enExample) |
| KR (1) | KR100292396B1 (enExample) |
| AT (1) | ATE181830T1 (enExample) |
| AU (1) | AU675935B2 (enExample) |
| CA (1) | CA2132544C (enExample) |
| DE (1) | DE69325574T2 (enExample) |
| DK (1) | DK0636027T3 (enExample) |
| ES (1) | ES2135472T3 (enExample) |
| GR (1) | GR3031261T3 (enExample) |
| HU (1) | HUT71331A (enExample) |
| NO (1) | NO313935B1 (enExample) |
| NZ (1) | NZ251741A (enExample) |
| WO (1) | WO1993020816A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT853477E (pt) * | 1995-10-06 | 2003-01-31 | Novartis Ag | Antagonistas de receptores at1 para prevencao e tratamento de insuficiencia renal pos-isquemica e para proteccao de rim isquemico |
| ES2189940T3 (es) | 1996-02-29 | 2003-07-16 | Novartis Ag | Antagonista de receptor at1 para la estimulacion de la apoptosis. |
| PL193365B1 (pl) * | 1996-04-05 | 2007-02-28 | Takeda Pharmaceutical | Kompozycja farmaceutyczna do zapobiegania lub zwalczania chorób związanych z angiotensyną II oraz zastosowanie związków do wytwarzania leku do zapobiegania lub zwalczania chorób związanych z angiotensyną II |
| US6465502B1 (en) | 1998-12-23 | 2002-10-15 | Novartis Ag | Additional therapeutic use |
| ATE354364T1 (de) | 1998-12-23 | 2007-03-15 | Novartis Pharma Gmbh | Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind |
| CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
| DE10335027A1 (de) | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| WO2006066361A1 (en) | 2004-12-24 | 2006-06-29 | The University Of Queensland | Method of treatment or prophylaxis |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| EP1908469A1 (en) | 2006-10-06 | 2008-04-09 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin II receptor antagonist for the treatment of systemic diseases in cats |
| US9095587B2 (en) | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| ES2979279T3 (es) | 2017-07-07 | 2024-09-25 | Boehringer Ingelheim Vetmedica Gmbh | Telmisartán para la profilaxis o el tratamiento de la hipertensión en gatos |
| AU2024277852A1 (en) | 2023-05-24 | 2025-10-16 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan |
| US20250195525A1 (en) | 2023-12-15 | 2025-06-19 | Boehringer Ingelheim Vetmedica Gmbh | Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT94960A (pt) * | 1989-08-11 | 1991-04-18 | Ici Plc | Processo para a preparacao de derivados de quinolina e de composicoes farmaceuticas que as contem |
| GB8927277D0 (en) * | 1989-12-01 | 1990-01-31 | Glaxo Group Ltd | Chemical compounds |
| US5140037A (en) * | 1990-03-20 | 1992-08-18 | E. I. Du Pont De Nemours And Company | Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists |
| US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
| GB9027211D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| GB9027210D0 (en) * | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| IL101860A0 (en) * | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| ATE152718T1 (de) * | 1991-08-15 | 1997-05-15 | Ciba Geigy Ag | N-acyl-n-heterocyclyl- oder naphthylalkyl- aminosäuren als angiotensin ii antagonisten |
-
1993
- 1993-04-07 DE DE69325574T patent/DE69325574T2/de not_active Expired - Fee Related
- 1993-04-07 AT AT93909041T patent/ATE181830T1/de not_active IP Right Cessation
- 1993-04-07 CA CA002132544A patent/CA2132544C/en not_active Expired - Fee Related
- 1993-04-07 EP EP93909041A patent/EP0636027B1/en not_active Expired - Lifetime
- 1993-04-07 DK DK93909041T patent/DK0636027T3/da active
- 1993-04-07 EP EP98108683A patent/EP0872235A1/en not_active Withdrawn
- 1993-04-07 HU HU9402932A patent/HUT71331A/hu not_active Application Discontinuation
- 1993-04-07 WO PCT/GB1993/000732 patent/WO1993020816A1/en not_active Ceased
- 1993-04-07 ES ES93909041T patent/ES2135472T3/es not_active Expired - Lifetime
- 1993-04-07 AU AU39589/93A patent/AU675935B2/en not_active Ceased
- 1993-04-07 JP JP5518094A patent/JPH07505646A/ja active Pending
- 1993-04-07 NZ NZ251741A patent/NZ251741A/en not_active IP Right Cessation
-
1994
- 1994-10-11 KR KR19940703608A patent/KR100292396B1/ko not_active Expired - Fee Related
- 1994-10-12 NO NO19943846A patent/NO313935B1/no not_active IP Right Cessation
-
1999
- 1999-09-20 GR GR990402358T patent/GR3031261T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9402932D0 (en) | 1995-02-28 |
| GR3031261T3 (en) | 1999-12-31 |
| HUT71331A (en) | 1995-11-28 |
| EP0636027B1 (en) | 1999-07-07 |
| NO313935B1 (no) | 2002-12-30 |
| CA2132544C (en) | 2005-10-18 |
| AU3958993A (en) | 1993-11-18 |
| AU675935B2 (en) | 1997-02-27 |
| ATE181830T1 (de) | 1999-07-15 |
| ES2135472T3 (es) | 1999-11-01 |
| EP0872235A1 (en) | 1998-10-21 |
| CA2132544A1 (en) | 1993-10-28 |
| NZ251741A (en) | 1997-06-24 |
| DE69325574D1 (de) | 1999-08-12 |
| NO943846L (no) | 1994-10-12 |
| EP0636027A1 (en) | 1995-02-01 |
| WO1993020816A1 (en) | 1993-10-28 |
| DK0636027T3 (da) | 2000-01-31 |
| KR100292396B1 (enExample) | 2001-09-17 |
| DE69325574T2 (de) | 2000-03-16 |
| NO943846D0 (no) | 1994-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07505646A (ja) | 神経伝達速度の減損を伴う障害，特に糖尿病性ニューロパシーに対するアンギオテンシンｉｉアンタゴニスト | |
| CA2336833C (en) | Remedy with antidepressant effects | |
| JP7594045B2 (ja) | 薬学的組成物 | |
| EP2343976A1 (en) | Methods of using sustained release aminopyridine compositions | |
| CA3090258A1 (en) | Use of (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus and acute sensorineural hearing loss | |
| JP2002539256A (ja) | 一定の親和性のあるｎｍｄａアンタゴニストの抗うつ剤としての使用 | |
| JP2002509540A (ja) | アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物 | |
| JP2003520237A (ja) | 鬱病及び関連疾患を治療するためのミルトラザピン及びジェピロンを含有する配合剤 | |
| JPH08511253A (ja) | アンギオテンシン変換酵素阻害剤とａ▲ｉｉ▼アンタゴニストとの組み合わせ | |
| JPH0320222A (ja) | 脳内虚血症治療剤 | |
| EA015483B1 (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ | |
| NL8002041A (nl) | Werkwijze voor het bereiden van een analgetisch en myotonolytisch geneesmiddel. | |
| US6448280B1 (en) | Angiotensin II antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy | |
| JP2003530350A (ja) | 外傷性脳損傷及びその他のニューロン障害治療用医薬 | |
| JP5127092B2 (ja) | 小脳機能障害を予防および治療するための２−アミノ−６−トリフルオロメトキシ−ベンゾチアゾールの使用 | |
| US20080255238A1 (en) | Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases | |
| JP2003524573A (ja) | 神経精神性疾患用ニコチンアンタゴニスト | |
| JP2004002353A (ja) | 医薬組成物 | |
| WO2004105756A2 (en) | Combination comprising (a) a neuroprotecting agent and (b) an agent binding to gadph and pharmaceutical use thereof | |
| WO1999007356A1 (en) | Nicotine antagonists for neuropsychiatric disorders | |
| JP3381198B2 (ja) | １，４−ジヒドロピリジンの糖尿病における使用 | |
| WO2017214157A1 (en) | Pharmaceutical formulations of nitrite uses thereof | |
| EP3967308A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
| JP2004175786A (ja) | Ｉ型アレルギー疾患治療用組成物 | |
| JP2002308769A (ja) | 止痒剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040309 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040609 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040909 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050719 |